Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)

NCT04646356 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT04646356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04646356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
Unity Health Toronto
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2020
Completion date
October 21, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epistaxis nosebleed, hereditary hemorrhagic telangiectasia